← Leaderboards
Hatice Hasturk
Boston University Medical Campus
$2,642,133
Attributed
$9,742,684
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–18$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$9,742,684 · 7
By mechanism
R01$7,290,951 · 1
U01$1,441,938 · 1
K23$647,325 · 1
M01$362,470 · 4
Top collaborators
- Thomas E Van Dyke7 shared
- Eric John Alm5 shared
- Floyd E Dewhirst5 shared
- Margaret J Duncan5 shared
- Daniel Irimia5 shared
- Daniel Segre5 shared
- Anne C Tanner5 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Thomas E Van Dyke$23,853,105
- Philippe Adam Grandjean$27,466,501
- Serge Dibart$1,446
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseInfectionPeriodontal DiseasesOral HealthResponseInflammatory ResponseInflammationOralNeutrophilProductionResearch PersonnelPeriodontitisMonocytePreventFutureCellsBacteriaMouth DiseasesPathogenesisFundingOral BacteriaAnti-Inflammatory AgentsAnti-InflammatoryClinical Research
Grant awards (19)
Cultivation, Nature, Ecology and Pathogenicity of the Uncultivable Oral Microbiom$1,445,827
R01 · FY2018 · DE
Cultivation, Nature, Ecology and Pathogenicity of the Uncultivable Oral Microbiom$1,435,407
R01 · FY2017 · DE
Phase 1/2 Clinical Trial to assess the safety and preliminary efficacy of Lipoxin Analog BLXA4-MEOral Rinse for the Treatment of Gingivitis$571,634
U01 · FY2017 · DE
Cultivation, Nature, Ecology and Pathogenicity of the Uncultivable Oral Microbiom$1,435,407
R01 · FY2016 · DE
Phase 1/2 Clinical Trial to assess the safety and preliminary efficacy of Lipoxin Analog BLXA4-MEOral Rinse for the Treatment of Gingivitis$870,304
U01 · FY2016 · DE
Cultivation, Nature, Ecology and Pathogenicity of the Uncultivable Oral Microbiom$1,465,407
R01 · FY2015 · DE
Cultivation, Nature, Ecology and Pathogenicity of the Uncultivable Oral Microbiom$1,508,903
R01 · FY2014 · DE
Treatment of Periodontitis and Inflammatory Changes in Diabetes$129,465
K23 · FY2012 · DE · contact PI
Treatment of Periodontitis and Inflammatory Changes in Diabetes$129,465
K23 · FY2011 · DE · contact PI
Treatment of Periodontitis and Inflammatory Changes in Diabetes$65,555
K23 · FY2010 · DE · contact PI
Treatment of Periodontitis and Inflammatory Changes in Diabetes$63,910
K23 · FY2010 · DE · contact PI
Treatment of Periodontitis and Inflammatory Changes in Diabetes$129,465
K23 · FY2009 · DE · contact PI
Treatment of Periodontitis and Inflammatory Changes in Diabetes$129,465
K23 · FY2008 · DE · contact PI
BIOLOGIC BASIS OF REFRACTORY PERIDONTAL DISEASE$82,996
M01 · FY2007 · RR · contact PI
BIOLOGIC BASIS OF REFRACTORY PERIDONTAL DISEASE$77,594
M01 · FY2006 · RR · contact PI
BIOLOGIC BASIS OF REFRACTORY PERIDONTAL DISEASE$121,549
M01 · FY2005 · RR
MICROBIAL CHARACTERIZATION OF INITIAL PERIODONTITIS$2,210
M01 · FY2005 · RR
Biologic Basis of Refractory Periodontal Disease$59,676
M01 · FY2004 · RR
Microbial Characterization of Initial Periodontitis$18,445
M01 · FY2004 · RR